Related Experiment Video
Updated: Jul 15, 2026
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Improving drug trials for mild to moderate Alzheimer's disease
1Health Sciences Centre, University of Calgary, Calgary, Alberta, Canada.
Abstract:
Over the last two decades, numerous studies have been conducted on subjects with mild to moderate Alzheimer's disease. The objective of this paper was to review concerns raised in the literature about the design and methodology of these clinical trials and to make recommendations to deal with the limitations identified. Concerns raised in the literature include the following: undue focus on statistical rather than clinical significance; the need for further pharmacoeconomic evaluations; the nonrepresentativeness of the study populations; perceived inadequacies in the direct-comparison studies conducted to date; the limitations of open-label extension studies; the inability of standard psychometric tools to document all the relevant treatment effects; the ethics of placebo-controlled trials; and, problems caused by the actions of the regulatory authorities. Recommendations are made to deal with the issues raised.
Insights
This review examines clinical trial designs for Alzheimer's disease, highlighting issues like statistical focus and non-representative populations. Recommendations are provided to improve future Alzheimer's research and drug development.
Area of Science:
- Neurology
- Clinical Trials
- Alzheimer's Disease Research
Background:
- Extensive research on mild to moderate Alzheimer's disease (AD) has been conducted over the past two decades.
- Clinical trials are crucial for developing effective AD treatments.
Purpose of the Study:
- To review critical concerns regarding the design and methodology of AD clinical trials.
- To propose recommendations for addressing identified limitations in AD research.
Main Methods:
- Literature review of studies on mild to moderate Alzheimer's disease.
- Analysis of concerns related to clinical trial design and methodology.
- Synthesis of recommendations for improving future trials.
Main Results:
- Identified concerns include: overemphasis on statistical significance, insufficient pharmacoeconomic evaluations, non-representative study populations, and inadequate direct-comparison studies.
- Further issues noted: limitations of open-label extension studies, inadequacy of standard psychometric tools, ethical considerations of placebo-controlled trials, and regulatory challenges.
- Recommendations are formulated to address these identified limitations.
Conclusions:
- Addressing methodological and design flaws is essential for advancing Alzheimer's disease research.
- Improved clinical trial practices will enhance the reliability and applicability of AD research findings.
- Recommendations aim to optimize the design and execution of future Alzheimer's clinical trials.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:11Clinical Trials: Overview
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:29Alzheimer Disease l: Introduction
01:15Drug Dosing: Geriatric Patients